{"id":"lysozyme-hydrochloride","safety":{"commonSideEffects":[{"rate":null,"effect":"Local irritation or burning at application site"},{"rate":null,"effect":"Allergic reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lysozyme is a naturally occurring enzyme that catalyzes the hydrolysis of β-1,4 glycosidic bonds in peptidoglycan, a major structural component of bacterial cell walls. This enzymatic degradation compromises bacterial cell wall integrity, leading to cell lysis and death. The drug is used topically or locally to provide antimicrobial activity against susceptible bacteria.","oneSentence":"Lysozyme hydrochloride is an antimicrobial enzyme that breaks down bacterial cell walls by cleaving peptidoglycan, thereby killing bacteria and reducing infection.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:53:45.778Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Bacterial infections (topical/local use)"},{"name":"Dry eye syndrome (as a component of tear substitutes)"}]},"trialDetails":[{"nctId":"NCT03282045","phase":"PHASE3","title":"Efficacy and Safety of the Lysobact Complete Spray®, Tantum Verde® and Pharyngal® Oromucosal Spray in the Treatment of Acute Sore Throat","status":"COMPLETED","sponsor":"Bosnalijek D.D","startDate":"2016-10","conditions":"Sore Throat","enrollment":346},{"nctId":"NCT01645800","phase":"PHASE4","title":"Effects of Lysozyme on Acute Exacerbation of Chronic Obstructive Pulmonary Disease : A Randomised Placebo-Controlled Study","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2012-08","conditions":"COPD","enrollment":408},{"nctId":"NCT01715493","phase":"PHASE4","title":"Pharmacological Effect of Lysozyme for Chronic Obstructive Pulmonary Disease and Asthma With Sputum Symptom","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2012-10","conditions":"Chronic Obstructive Pulmonary Disease, Asthma","enrollment":48}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":13,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Lysozyme hydrochloride","genericName":"Lysozyme hydrochloride","companyName":"Eisai Co., Ltd.","companyId":"eisai","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lysozyme hydrochloride is an antimicrobial enzyme that breaks down bacterial cell walls by cleaving peptidoglycan, thereby killing bacteria and reducing infection. Used for Bacterial infections (topical or systemic use), Dry eye syndrome (xerophthalmia).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}